Skip to main content
. 2022 Apr 27;9(6):1608–1623. doi: 10.1016/j.gendis.2022.04.004

Figure 7.

Figure 7

Molecular immunology of immunotherapies for melanoma. Naïve T cells can be activated by interacting with dendritic cells (DC) through T-cell receptor (TCR), which is inhibited by B7/CTLA-4 interaction. Activated T cells launch immune attack on melanoma cells, which can be inhibited by PD-L1/PD-1 interaction. Therefore, targeted immunotherapeutic antibodies have been developed to inhibit CTLA-4, PD-L1 and/or PD-1 to treat melanoma and other types of cancer. The illustrations were inspired by BioRender.